Variation in Gingival Inflammatory Responses

Inclusion Criteria: * Provide signed and dated informed consent form * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged 18-35 years * Good general health, ASA I (healthy with no systemic conditions) * No clinical signs of gingival inflammation at \> 90% of sites observed (whole mouth) (\< 10% of sites with GI of \< 2 and no sites with a score of 3; \< 10% sites with BOP +). * Probing depth (PD) ≤ 3.0 mm (Whole Mouth) * Attachment loss (AL) = 0 mm (Whole Mouth) * Gingival health at Visit 2 (Day 0) for study sites (Test/Control teeth): Average Gingival Index (GI) ≤ 0.1 with no site having a score of 3 and bleeding on probing (BOP)(-) * Never smokers * The ability to understand and communicate with the examiner. * Willing and able to comply with study procedures. Exclusion Criteria: * Medical condition which requires premedication prior to dental treatments/visits * Subjects unable or unwilling to sign the informed consent form * History of periodontal disease * History of systemic inflammatory or immune conditions, Diabetes * Use of antibiotic or anti-inflammatory drugs within 30 days of enrollment * Self-reported pregnancy, planned pregnancy during the planned study commitment, and/or breastfeeding at the time of screening. * Concurrent orthodontic treatment * Untreated carious lesions and/or inadequate restorations on maxillary posterior teeth * Participation in any other clinical study or test panel within 1 week prior to enrollment into this study * Use of tobacco products * Subjects who must receive dental treatment during the study dates * Orthodontic bands, appliances, or crowns and bridges, or removable partial dentures affecting the maxillary posterior teeth * Missing tooth/teeth within the study sites test and control * History of allergy to common dentifrice ingredients * Immune-compromised individuals (for example: HIV, AIDS, and immune-suppressive drug therapy)